Venous thromboembolism (VTE), the third leading cause of cardiovascular mortality, is a complex thrombotic disorder with environmental and genetic determinants. Although several genetic variants have been found associated with VTE, they explain a minor proportion of VTE risk in cases. We undertook a meta-analysis of genome-wide association studies (GWASs) to identify additional VTE susceptibility genes. Twelve GWASs totaling 7,507 VTE case subjects and 52,632 control subjects formed our discovery stage where 6,751,884 SNPs were tested for association with VTE. Nine loci reached the genome-wide significance level of 5 3 10 À8 including six already known to associate with VTE (ABO, F2, F5, F11, FGG, and PROCR) and three unsuspected loci. SNPs mapping to these latter were selected for replication in three independent case-control studies totaling 3,009 VTE-affected individuals and 2,586 control subjects. This strategy led to the identification and replication of two VTE-associated loci, TSPAN15 and SLC44A2, with lead risk alleles associated with odds ratio for disease of 1. 532 The American Journal of Human Genetics 96, 532-542, April 2, 2015 transfusion-related acute lung injury. We further showed that these two variants did not associate with known hemostatic plasma markers. TSPAN15 and SLC44A2 do not belong to conventional pathways for thrombosis and have not been associated to other cardiovascular diseases nor related quantitative biomarkers. Our findings uncovered unexpected actors of VTE etiology and pave the way for novel mechanistic concepts of VTE pathophysiology.
transfusion-related acute lung injury. We further showed that these two variants did not associate with known hemostatic plasma markers. TSPAN15 and SLC44A2 do not belong to conventional pathways for thrombosis and have not been associated to other cardiovascular diseases nor related quantitative biomarkers. Our findings uncovered unexpected actors of VTE etiology and pave the way for novel mechanistic concepts of VTE pathophysiology.
Introduction
Venous thromboembolism (VTE [MIM 188050]) is a common multicausal thrombotic disease with an annual incidence of 1 per 1,000. It includes two main clinical manifestations: deep vein thrombosis (DVT) and pulmonary embolism (PE). The latter is associated with a 1-year mortality of 20%, making VTE the third leading cause of cardiovascular death in industrialized countries. 1 Moreover, among survivors, 25%-50% will have lasting debilitating health problems such as post-thrombotic syndrome, severely hampering mobility and quality of life. Factors contributing to VTE include endothelial injury or activation, reduced blood flow, and hypercoagulability of the blood, the so-called Virchow triad. 2 Venous thromboembolism has a strong genetic basis that is characterized by an underlying heritability estimate of 50% and a risk of developing the disease in an individual with an affected sib 2.5 higher than for the general population. 3, 4 But, like other complex phenotypes, most genetic contributors have not been elucidated because the proportion of heritability explained by replicated variants has been small. 5, 6 There are seven well-established genetic risk factors for VTE, all responsible for inherited hypercoagulable states. The first three are heterozygous deficiencies of the natural coagulation inhibitors (antithrombin, protein C, and protein S). These deficiencies are relatively rare, affecting <1% of the general population, and they increase VTE risk by approximately ten. The other four, Factor V (FV [MIM 612309]) Leiden, prothrombin (MIM 176930) G20210A, fibrinogen g' (FGG) (MIM 134850) rs2066865, and blood group non-O, are more frequent with prevalence in European-descent individuals around 5% for the former two and~25% for the latter two. The increase in VTE risk is about 3-fold for the FV Leiden (RefSeq accession number NP_000121.2, p.Arg534Gln [c.1601G>A]) and prothrombin G20210A (RefSeq NM_000506.3, c.*97G>A) mutations, 2-fold for non-O blood group, and 1.5-fold for FGG rs2066865. 7 The genome-wide association strategy is a powerful method to identify common SNPs associated with a complex disorder without a pre-specified hypothesis. Although previous genome-wide association studies (GWASs) have been reported for VTE, none has included more than 1,961 case subjects 5, 6 and none has yielded new genetic loci. In this article, we report the largest investigation to date of the influence of common genetic variations on VTE risk by meta-analyzing GWAS findings from 12 studies.
Subjects and Methods

Study Design
We report on a three-stage investigation of common genetic predictors of VTE. A discovery phase included 7,507 VTE case subjects and 52,632 control subjects from 12 studies and a replication phase included 3,009 case subjects and 2,586 control subjects from three independent studies. In addition, confirmed discoveries were then examined for association with quantitative biomarkers of VTE risk, gene expression in various tissues and cell types, as well as with whole blood DNA methylation levels.
Participants in Discovery and Replication
For the discovery phase, participants were European-ancestry adults in two French case-control studies, two Dutch case-control studies, and four cohort and four case-control studies from the United States. Details of each study have been previously published. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Three other French case-control studies for VTE were used for the replication stage. 11, 20 In all studies, VTE (PE or DVT)
was objectively diagnosed by physicians using different techniques including compression venous duplex ultrasonography, computed tomography, Doppler ultrasound, impedance plethysmography, magnetic resonance, venography, pulmonary angiography, and ventilation/perfusion lung scan. VTE events related to cancer, autoimmune disorders, or natural anticoagulant inhibitor deficiencies (protein C, protein S, antithrombin) were excluded in most studies. A detailed description of the design and the clinical characteristics of all VTE studies analyzed in this work is presented in Table S1 . All participating studies were approved by their respective institutional review board and informed consent was obtained from studied individuals.
Genotyping and Imputation
Within each discovery study, DNA samples were genotyped with high-density SNP arrays and were imputed for SNPs available in the 1000 Genomes reference dataset. Summary descriptions of genotyping technologies, quality-control procedures, and imputation methods used for the discovery cohorts are shown in Table S1 .
In the replication studies, genotyping of the selected SNPs was performed by allele-specific PCR.
Association Analyses and Meta-Analysis for Discovery
Association analyses of imputed SNPs with VTE risk were performed separately in each study by using logistic or Cox-proportional regression analyses adjusted for study-specific covariates (Table S1 ). All SNPs with acceptable imputation quality (r 2 > 0.3) 21 in all 12 discovery studies and with estimated minor allele frequency greater than 0.005 were entered into a meta-analysis.
For the meta-analysis, a fixed-effects model based on the inversevariance weighting was employed as implemented in the METAL software. 22 A statistical threshold of 5 3 10 À8 controlling for the number of independent tests across the genome was applied to declare genome-wide significance. 21, 23, 24 Heterogeneity of the SNP associations across studies was tested with the Cochran's Q statistic and its magnitude expressed by the I 2 index.
Association Analyses and Meta-Analysis for Replication
In the replication cohorts, association of tested SNPs with VTE risk was assessed by use of logistic regression under the assumption of additive allele effects, adjusting for age and sex. Results obtained in the replication cohorts were meta-analyzed via a fixed-effects model based on the inverse-variance weighting as implemented in the METAL software. 22 A statistical threshold of 0.05 divided by the number of replications performed was used to declare statistical replication. Heterogeneity of the SNP associations across studies and subgroups of individuals (e.g., PE versus DVT) was tested via the Cochran's Q statistic and its magnitude expressed by the I 2 index. For replicated SNPs, meta-analyses of all studies were performed to produce the most robust estimate of the effect size.
Conditional Analysis to Discover Independent Signals at Replicated Loci
To test for the presence of additional independent VTE-associated SNPs at each of the replicated loci, we re-analyzed in each discovery study a GWAS conditioning on the imputed allelic dose of each replicated SNP and meta-analyzed the results by the same strategy as the original GWAS analysis. Areas within 200 kb up-and downstream of the SNPs were examined.
Biologic Follow-up on Replicated Findings
The influence of replicated SNPs on the variability of hemostatic traits known to associate with VTE pathophysiology and measured in our available cohorts was assessed to learn more about biologic pathways. Investigated quantitative biomarkers were D-dimers, endogenous thrombin generation, plasma antigen or activity levels of fibrinogen, coagulation factors II, VII, VIII, IX, X, and XII, von Willebrand factor, antithrombin, protein C, protein S (total and free), protein Z, activated partial thromboplastin time, hemoglobin, and white blood cell and platelet counts. Associations of replicated SNPs with these quantitative hemostatic traits were investigated in five cohorts that were part of the discovery and replication stages by using linear regression analyses adjusted for age-, sex-, and cohort-specific covariates. The overall statistical evidence for association with a given phenotype across available cohorts was assessed by use of the Fisher combined test statistics to account for different measurement methods used across studies. Replicated SNPs were examined for association with the expression of their structural genes via publicly available genome-wide gene expression data from multiple cell lines and tissues. Impact of replicated lead SNPs on DNA methylation levels from peripheral blood DNA was also investigated.
Results
After applying quality-control measures, 6,751,884 SNPs were tested for association with VTE in a total of 7,507 case subjects and 52,632 control subjects. The Manhattan and Q-Q plots of the meta-analysis of GWAS results are shown in Figures S1-S4. A total of 1,060 SNPs clustered into nine chromosomal regions and reached the genomewide significance level of p < 5 3 10 À8 . The rs4524 was associated with VTE risk independently of the rs6025 variant. d The rs2288904 was not the lead SNP observed at the SLC44A2 locus. However, because it is a non-synonymous polymorphism with strong evidence for functionality that is in strong LD (r 2~1 ) with the lead intronic rs2360742 (p ¼ 5.6 3 10 À10 ), it was the one taken forward for replication.
Among the nine loci that were genome-wide significant in the discovery scan, six were already known to be associated with VTE (ABO [ were in high linkage disequilibrium (LD) with their lead SNPs. We attempted replication of TSPAN15 rs78707713, SLC44A2 rs2288904, and ZFPM2 rs4602861 SNPs in the meta-analysis of three independent studies totaling 3,009 VTE-affected individuals and 2,586 control subjects. We did not observe any evidence for association of ZFPM2 rs4602861 with VTE risk, overall or in any of the three replication studies (Table 2) , despite having 93% power in the combined replication studies to detect at the 0.017 (¼0.05 / 3) statistical threshold the effect of a SNP with RAF 0.76 and associated with an OR of 1.20. 25 Conversely, we confirmed association for TSPAN15 rs78707713 and SLC44A2 rs2288904 SNPs (Table 2 ). In meta-analyzed replication results, the common TSPAN15 rs78707713-T allele was associated with an OR for VTE of 1.42 (p ¼ 2.21 3 10 À7 ) ( Figure S5 ), and the common SLC44A2 rs2288904-G allele with an increased risk of 1.28 (p ¼ 2.64 3 10 À7 ) ( Figure S6 ). When the results obtained in the discovery and the replication studies were metaanalyzed, the summary OR for VTE was 1.31 (p ¼ 1.67 3 10 À16 ) for TSPAN15 rs78707713 ( Figure S5 ) and 1. Visual inspection of the regional association plots at the TSPAN15 (Figure 1 ) and SLC44A2 (Figure 2 ) suggested that all SNPs at these loci with high level of significance for association with VTE were in strong LD with the lead SNPs. This was confirmed by the results of the conditional analysis that did not produce any other signal significant at the 5 3 10 À8 statistical threshold. After adjusting for rs78707713, the lowest p value observed at TSPAN15 was p ¼ 4.92 3 10 À4 for the intronic rs1072160 (Figure 1 ). Conditioning on rs2288904 abolished all associations at the SLC44A2 locus, the lowest p value then being p ¼ 0.047 for the KEAP1 rs45524632 (Figure 2 ). In subgroup analyses of the replication studies, the genotype distribution of TSPAN15 rs78707713 and SLC44A2 rs2288904 did not differ according to the clinical manifestations of VTE, either PE or DVT (Table S2) . We did not observe heterogeneity in the effects of the two SNPs according to sex nor to F5 rs6025 or F2 rs1799963 mutations (Tables S3 and S4 ). Although the six known VTE-associated loci affect VT risk through a modulation of known hemostatic traits (i.e., levels of von Willebrand factor and Factor VIII for ABO, of FXI for F11, of endogenous thrombin potential for F2, of resistance to activated protein C for F5, of fibrinogen for FGG, and of protein C for PROCR [26] [27] [28] [29] [30] [31] [32] [33] ), the loci of the two discovered genetic associations were not in or near genes that are currently known to influence hemostasis. We then explored whether these SNPs were associated with well-characterized hemostasis phenotypes that are associated with thrombotic propensity. We did not find any evidence for an association with 25 plasma biomarkers (Table S5 ) even though the sample size of the investigated studies were sufficiently statistically powered (~95%) to detect the additive allele effect of any SNP that would explain 1% of the variability of a quantitative trait. 34 By contrast, the anticipated effects of the six known VTE-associated loci were observed in these studies (Table S6) .
We interrogated genome-wide gene expression in ten tissues and DNA methylation studies in blood to determine whether the TSPAN15 and SLC44A2 SNPs influenced the regulation of their associated genes. We observed significant associations of the TSPAN15 rs78707713 with TSPAN15 DNA methylation measured from peripheral blood DNA and TSPAN15 expression in macrophages, endothelial cells, and esophagus mucosa ( Table 3 ). The SLC44A2 rs2288904 was found significantly associated with SLC44A2 gene expression in monocytes, macrophages, and whole blood (Table 4) . However, for none of the interrogated bio-resources for gene expression or DNA methylation levels did the identified disease-associated SNPs show the strongest locus-wide effects. Of note, most SNPs that demonstrated the greatest influence on gene regulation at the replicated loci showed weak or null associations with VTE risk (Tables 3 and 4) . Further analyses revealed that the observed effects of TSPAN15 rs78707713 and SLC44A2 rs2288904 on gene expression and DNA methylation were probably due to their linkage disequilibrium with other regulatory variants with stronger effects (data not shown).
Discussion
By using data from more than 7,000 case subjects and more than 50,000 control subjects, which represents a 4-fold increase in the number of VTE events used in our discovery effort compared with that used in the latest meta-analysis of GWASs for VTE, we identified and then replicated two associations for common variants in TSPAN15 and SLC44A2. The strengths of the associations were modest in size with ORs of 1.3 or less, but the statistical evidence was robust in the discovery and replication stages. Further, we observed that the variants were not associated with dozens of hemostatic markers characterizing the coagulation/fibrinolysis balance. The identified VTE-associated SNPs map to genes that are not in conventional pathways to thrombosis that have marked most of the genetic associations to date, suggesting that these genetic variants represent novel biological pathways leading to VTE.
The common T allele, with frequency~0.89, of the identified TSPAN15 rs78707713 was associated with an increased risk of 1.31-fold. The TSPAN15 rs78707713 is intronic and the interrogation of several gene expression databases as well as the application of prediction/annotation tools [46] [47] [48] did not suggest any regulatory elements supporting a functional role of this SNP. It is likely that the SNP is in strong LD with yet unidentified culprit variant(s). For instance, rs78707713 is in strong LD (pairwise r 2 ¼ 0.89) with the intronic TSPAN15 rs17490626 predicted 46, 47 to map an enhancer domain, the significance of the VTE association of the latter SNP being p ¼ 3.74 3 10 À10 . No association of TSPAN15-coding SNPs with VTE risk was observed in the discovery meta-analysis (smallest p value ¼ 0.49). TSPAN15 codes for tetraspanin 15, a member of the tetraspanin superfamily that act as scaffolding proteins, anchoring multiple proteins to the cell membrane. 49 Members of the tetraspanin family have roles in cells that regulate hemostasis. TSPAN24 (CD151)- 50 and TSPAN32 (TSSC6)-51 deficient mice exhibit a bleeding phenotype with impaired ''outside-in'' signaling through a IIb b 3 , the major platelet integrin. CD63 (TSPAN30) facilitates the release of von Willebrand factor (VWF) from endothelial cell Weibel-Palade bodies through transient enhancement of fusion between the Weibel-Palade body membrane and the plasma membrane, 52 which probably contributes to the leucocyte attachment to the endothelium. 53 The risk allele at the second identified locus, SLC44A2 rs2288904-G, was also common, with frequency~0.77. It was associated with a relative risk of 1.21 and is probably the functional variant. Indeed, the observed risk allele (G) codes for the Arg154 isoform of the choline transporter-like protein 2 (CTL-2). CTL-2 has been associated with several human diseases, 54 including transfusionrelated acute lung injury (TRALI). TRALI is a life-threatening complication of blood transfusion and the leading cause of transfusion-associated mortality in developed countries. Severe TRALI is due to antibodies in blood components directed against the human neutrophil alloantigen-3a (HNA-3a), which is determined by the Arg154 isoform. 55, 56 Greinacher et al. 55 found that alloantibodies targeting CTL-2 lead to leucocyte activation and aggregation. Recently, human anti-HNA-3a antibodies were shown to directly interact with endothelial CTL-2 to disturb pulmonary endothelial barrier function that would lead to severe TRALI. 57 It might be that carrying the HNA3a antigen, determined by the Arg154 isoform, favors activation of leucocytes/neutrophils and endothelial cells in some triggering circumstances. We did not observe any difference in TSPAN15 and SLC44A2 VTE-associated SNP allele frequencies between DVT-and PE-affected individuals in the replication populations, the two main clinical manifestations of VTE. This observation suggests that the underlying pathophysiological mechanisms are more likely to be involved in thrombus formation rather than its rupture and its migration toward the pulmonary vein. About 20% of persons with unprovoked VTE (i.e., occurring without clear external factors like surgery, trauma, immobilization, hormone use, or cancer) will experience a recurrent event, even after a 6-month course of anticoagulant prophylaxis. Because we had little information about recurrence followup in our studies, we were not able to assess whether the identified SNPs can discriminate between individuals that will and those that will not face a recurrent event. Investigating whether these SNPs can help improve the secondary prevention of VTE would definitively be warranted.
Despite having gathered the largest GWAS samples of VTE-affected individuals, our approach was not well powered to identify common SNPs associated with more modest effects than those observed for SLC44A2 and TSPAN15, i.e., with OR < 1.20, or extremely rare mutations (e.g., with frequency < 1%) that cannot be efficiently tagged by the tested SNPs (Table S7) . Heterogeneity in the design and clinical characteristics of the studied populations might also have contributed to slightly attenuate the power of our study to detect additional genome-wide significant associations. Further investigations deserve to be conducted to better characterize the 202 suggestive statistical associations with p < 10 À5 in our discovery meta-analysis and to identify additional susceptibility loci for VTE. Though additional work is needed, including the identification of the functional TSPAN15 variant(s), our results demonstrated that SLC44A2 and TSPAN15 are two susceptibility loci for VTE. The products of the two genes, expressed by cells that are central to the pathophysiology of thrombosis (monocytes/macrophages and endothelial cells), are not known to have central roles in the traditional hemostasis pathways nor to other cardiovascular diseases. These results pave the way for novel mechanistic concepts of VTE pathophysiology, new biomarkers for the disease, and novel therapeutic perspectives.
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Of note, no CpG probe targeting the SLC44A2 locus satisfied the adopted quality-control procedures, preventing us from efficiently testing for the effect of SLC44A2 rs2288904 on DNA methylation levels at this locus in the interrogated bio-resources. a Pairwise r 2 was derived from the SNAP database 45 except for result noted with asterisk (*) where linkage disequilibrium was estimated from the MARTHA GWAS imputed genotypes.
